Nicholas Keat

Nicholas Keat

Auto-generated profile, based on publicly available information

Nicholas Keat

Imanova Limited, Imperial College London, Hammersmith Hospital, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in RadioGraphics
Verified
Journal Article
Closed access
JBJulia F. Barrett
Julia F. Barrett
NKNicholas Keat
Nicholas Keat
Artifacts can seriously degrade the quality of computed tomographic (CT) images, sometimes to the point of making them diagnostically unusable. To optimize image quality, it is necessary to understand why artifacts occur and how they can be prevented or suppressed. CT artifacts originate from a range of sources. Physics-based artifacts result from the physical processes involved in the acquisition of CT data. Patient-based artifacts are caused by such factors as patient movement or the presence of metallic materials in or on the patient. Scanner-based artifacts result from imperfections in scanner function. Helical and multisection technique artifacts are produced by the image reconstruction process. Design features incorporated into modern CT scanners minimize some types of artifacts, and some can be partially corrected by the scanner software. However, in many instances, careful patient positioning and optimum selection of scanning parameters are the most important factors in avoiding CT artifacts.

12 May 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SDsuraiya dubash
suraiya dubash
NKNicholas Keat
Nicholas Keat
PMPaola Mapelli
Paola Mapelli
FTFrazer Twyman
Frazer Twyman
LCLaurence Carroll
Laurence Carroll
EAEric Ofori Aboagye
Eric Ofori Aboagye
We conducted the first-in-human study of 18F-fluoroethyl triazole [Tyr3] octreotate (18F-FET-βAG-TOCA) in patients with neuroendocrine tumors (NETs) to evaluate biodistribution, dosimetry, and safety. Despite advances in clinical imaging, detection and quantification of NET activity remains a challenge, with no universally accepted imaging standard. Methods Nine patients were enrolled. Eight patients had sporadic NET and one had multiple endocrine neoplasia type 1 (MEN1) syndrome. Patients received 137-163MBq (mean 155.7± 8 MBq) of 18F-FET-βAG-TOCA. Safety data were obtained during and 24 h after radioligand administration. Patients underwent detailed whole body PET-CT multi-bed scanning over 4 h with sampling of venous bloods for radioactivity and radioactive metabolite quantification. Regions of interest were defined to derive individual and mean organ residence times; effective dose (ED) was calculated with OLINDA 1.1. Results All patients tolerated 18F-FET-βAG-TOCA with no adverse events. Over 60% parent radioligand was present in plasma at 60 min. High tumor (primary and metastases)-to-background contrast images were observed. Physiological distribution was seen in pituitary, salivary, thyroid and spleen, with low background distribution in liver, an organ where metastases commonly occur. The organs receiving highest absorbed dose were gallbladder, spleen, stomach, liver, kidneys and bladder. The calculated ED over all subjects (mean ± SD) was 0.029 ± 0.004 mSv/MBq. Conclusion The favorable safety, imaging and dosimetric profile makes 18F-FET-βAG-TOCA a promising candidate radioligand for staging and management of NETs. Clinical studies in an expanded cohort are ongoing to clinically qualify this agent.

1 December 2001 in British Journal of Radiology
Verified
Journal Article
Closed access
NKN Keat
N Keat

1 January 2007 in Japanese Journal of Radiological Technology
Verified
Journal Article
Closed access
PDF file
YMYoshihisa Muramatsu
Yoshihisa Muramatsu
SIShu Ikeda
Shu Ikeda
KOKazuaki Osawa
Kazuaki Osawa
RSRyo Sekine
Ryo Sekine
NNNobuyuki Niwa
Nobuyuki Niwa
SMShigeru Miyazaki
Shigeru Miyazaki
Although many current CT scanners incorporate CT-AEC, performance evaluation is not standardized. This study evaluates the performance of the latest CT-AEC of each manufacturer with the aim of establishing a standard CT-AEC performance evaluation method. The design of the phantoms was based upon the operation characteristics of different CT-AECs. A cone, an ellipse, a variable-shaped ellipse, stepped phantoms, and their analysis software were devised and carried out the field test. The targets were LightSpeed VCT 64 with 2D and 3D Auto mA(GE), Aquilion 64M with Real-EC and Volume-EC(Toshiba), Sensation 64 with CARE Dose and CARE Dose 4D(Siemens), and Bulliance 16P with Dose Right(Philips). Data was acquired while varying the typical abdominal CT(with CT-AEC)scanning conditions (120 kV, 5 mm slice, standard function for abdomen, scanning range 200 mm). The acquired images were converted to the DICOM format and image noise(SD) was calculated using dedicated software. All 4 CT-AECs reduced exposure dose. For GE and Toshiba, image noise was constant and met the target. For Siemens, noise was independent of phantom shape but varied uniformly with phantom size. For Philips, noise varied with phantom size and shape, and variation degree depended on phantom thickness in scanogram direction. The results reflect the basic concept and performance characteristics of the methods. Standardization of CT-AEC performance evaluation is possible using these phantoms.

2 February 2018 in Journal of Nuclear Medicine Technology
Verified
Journal Article
Closed access
PDF file
NKNicholas Keat
Nicholas Keat
JKJulia Kenny
Julia Kenny
KCKeguan Chen
Keguan Chen
MOMayca Onega
Mayca Onega
NGNadia Garman
Nadia Garman
PLPauline T Lukey
Pauline T Lukey
The αvβ6 integrin is involved in the pathogenesis of cancer and fibrosis. A radio-labelled 20-amino acid αvβ6-binding peptide, derived from the foot and mouth virus (A20FMDV2), has been developed to image αvβ6 levels pre-clinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ6 in humans. Methods: Pre-clinical toxicology was undertaken and a direct immunoassay was developed for FB-A20FMDV2. A first time in human study of [18F]FB-A20FMDV2 was conducted in four healthy subjects (two males and two females). Each subject received a single microdose of [18F]FB-A20FMDV2. Subjects underwent a multibed positron emission tomography (PET) scan of the whole body over 3+ hours. Results: There were no findings in the pre-clinical toxicology assessments and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and standard deviation of the administered mass of [18F]FB-A20FMDV2 was 8.7 ± 4.4 µg (range, 2.7–13.0 mg). The mean administered activity was 124 ± 20 MBq (range, 98–145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the [4] subjects. No significant changes in vital signs or the results of laboratory studies or electrocardiograms were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, ureters and bladder. Time-activity curves indicated that the highest activity was observed in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder and liver. Using the mean residence time over all subjects as input to Organ Level INternal Dosimetry Assessment/EXponential Modelling software (OLINDA/EXM), the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave a standard deviation of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion: [18F]-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in healthy subjects and has an effective dose that enables multiple scans in a single subject.

30 July 2018 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
AVAshwin V. Venkataraman
Ashwin V. Venkataraman
NKNicholas Keat
Nicholas Keat
JMJames F. Myers
James F. Myers
STSamuel Turton
Samuel Turton
IMInge Mick
Inge Mick
DNDavid Nutt
David Nutt
We measured whole body distribution of 11C-BU99008, a new PET biomarker for non-invasive identification of the imidazoline2 binding site. The purpose of this phase I study was to evaluate the biodistribution and radiation dosimetry of 11C-BU99008 in healthy human subjects. A single bolus injection of 11C-BU99008 (296 ± 10.5 MBq) was administered to four healthy subjects who underwent whole-body PET/CT over 120 min from the cranial vertex to the mid-thigh. Volumes of interest were drawn around visually identifiable source organs to generate time-activity curves (TAC). Residence times were determined from time-activity curves. Absorbed doses to individual organs and the whole body effective dose were calculated using OLINDA/EXM 1.1 for each subject. The highest measured activity concentration was in the kidney and spleen. The longest residence time was in the muscle at 0.100 ± 0.023 h, followed by the liver at 0.067 ± 0.015 h and lungs at 0.052 ± 0.010 h. The highest mean organ absorbed dose was within the heart wall (0.028 ± 0.002 mGy/MBq), followed by the kidneys (0.026 ± 0.005 mGy/MBq). The critical organ was the heart wall. The total mean effective dose averaged over subjects was estimated to be 0.0056 ± 0.0004 mSv/MBq for an injection of 11C-BU99008. The biodistribution of 11C-BU99008 has been shown here for the first time in humans. Our dosimetry data showed the total mean effective dose over all subjects was 0.0056 ± 0.0004 mSv/MBq, which would result in a total effective dose of 1.96 mSv for a typical injection of 350 MBq of 11C-BU99008. The effective dose is not appreciably different from those obtained with other 11C tracers.